Veru Reports Fiscal 2025 Third Quarter Financial Results and Clinical Program Progress
Provided By GlobeNewswire
Last update: Aug 12, 2025
--Company reported positive efficacy and safety data from Phase 2b QUALITY study showing enobosarm added to semaglutide led to preservation of muscle, greater fat loss, and fewer gastrointestinal side effects compared to semaglutide alone--
Read more at globenewswire.com
